Poster Session A
Friday, March 2, 2018
4:30 p.m. – 7:00 p.m.
Grand Ballroom DEF


A02 Delineating differential transcriptional roles for the ZBTB family of methyl-CpG binding proteins in cancer. Bethany Buck-Koehntop, University of Utah, Salt Lake city, UT.

A03, PR01 DNA and histone methyltransferase inhibitors cooperate to increase viral mimicry in cancer cells. Minmin Liu, Van Andel Research Institute, Grand Rapids, Michigan.

A04 UHRF1 depletion and HDAC inhibition synergistically reanimate epigenetically silenced genes in colorectal cancer cells. Hiromu Suzuki, Sapporo Medical University, Sapporo, Hokkaido, Japan.

A05, PR02 Investigating the mechanisms by which ZBTB38 recognizes methylated DNA and modulates transcription. Nicholas Hudson, University of Utah, Salt Lake City, Utah.

A07, PR03 Mismatch repair proteins initiate epigenetic alterations during inflammation-driven tumorigenesis. Heather O’Hagan, Indiana University School of Medicine, Bloomington, IN.

A08 Epigenetic characterization of cancer-associated fibroblasts: Implication for epigenetic reprogramming therapy. Masahiro Maeda, Division of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan.

A09 Epigenome and transcriptome analyses by Methyl-seq and RNA-seq on the protective effects of ursolic Acid against UVB-irradiated inflammation in Nrf2 knockout and wild-type C57BL/6J Mice. Yuqing (Anne) Yang, Rutgers University, Piscataway, NJ.

A10, PR07 Synthetic lethal targeting of TET2 loss in myeloid malignancies by TOP1 inhibitors. Chang-Bin Jing, Dana-Farber Cancer Institute, Boston, MA.

A11 Loss of hydroxymethylcytosine is an independent adverse prognostic factor in clear cell Renal Cell Carcinoma (ccRCC) and can be abrogated by Ascorbic acid mediated TET activation. Niraj Shenoy, Mayo Clinic Rochester, Rochester, MN.

A12, PR05 Genome-wide 5-hydroxymethylcytosine alterations in medulloblastoma. Hyerim Kim, Emory University, Atlanta, Georgia.

A13 Mutational cooperativity of TET2 in peripheral T cell lymphoma. Yun Huang, Texas A&M University, Houston, TX.

A14, PR08 Identification of specific readers of epigenetic modifications in human bronchial epithelial cells using a quantitative proteomics approach. Jenna Fernandez, Masonic Cancer Center, Minneapolis, MN.

A16 Safety and tolerability of guadecitabine (SGI-110) plus cisplatin in patients with platinum-refractory germ cell tumors (GCT): a phase 1 study. Costantine Albany, Indiana University, Indianapolis, IN.
A17 Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor SGI-110 in Hepatocellular Carcinoma Cells. Gangning Liang, Norris Comprehensive Cancer Center, Los Angeles, California.

A18 Rigosertib (RIG) Alone or in Combination with Azacitidine or Vorinostat has chromatin modifying effects and Epigenetically Reprograms Hematopoietic stem and progenitor cells in the Myelodysplastic Syndrome. Lewis Silverman, Icahn School of Medicine, New York, New York.

A19, PR06 Relapsing and refractory acute myeloid leukemia patients reveal converging genetic and epigenetic features suggesting common treatment strategies and response biomarkers. Timothy Triche, VARI, Grand Rapids, MI.

A20 Profiling breast cancer for decitabine response indicators reveals deoxycytidine kinase as key determinant of sensitivity. Margaret Thomas, Dalhousie University, Halifax, NS, Canada.

A21 Decitabine as a new therapeutic agent for T-cell acute lymphoblastic leukemia. Morgan Thénoz, Center for Medical Genetics (CMGG), Ghent University Hospital, Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

A22 Preclinical study of epigenetic drug-based differentiation therapy for neuroblastoma. Naoko Hattori, National Cancer Center Research Institute, Tokyo, Japan.

A23 A phase I trial of the epigenetic regulators, oral 5-azacitidine and romidepsin, for the treatment of advanced solid tumors, with a focus on virally mediated cancers and liposarcoma. Stephanie Gaillard, Johns Hopkins School of Medicine, Baltimore, MD.

A24 Development of gene regulation pyrrole-imidazole polyamides targeting the epigenetic deregulation biomarkers in oral squamous cell carcinoma. TZE-TA HUANG, Institute of Oral Medicine, National Cheng Kung University, Tainan, Taiwan.


A26 DNA methylation signatures associated with pituitary macroadenomas functional status. Maritza Mosella, Henry Ford Health System, Detroit, MI.

A27 Epigenetic regulation in Ewing sarcoma. Sheetal Mitra, Children's Hospital Los Angeles, Los Angeles, California.

A28 Using LacZ reporter to investigate L1 expression and epigenetic regulation during mouse development. Wenfeng An, South Dakota State University, Brookings, SD.


A31 ZBTB46 is a novel oncogene that contributes to castration-resistant prostate cancer through activation of microRNA-1 DNA methylation. Yen-Nien Liu, Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan, Taiwan.

A32, PR10 Targeting CDK9 reactivates epigenetically silenced genes in cancer. Hanghang Zhang, Fels Institute for Cancer Research, Temple University School of Medicine, Philadelphia, PA.

A33 CTCs contribution in cancer therapy and progression. Nise Yamaguchi, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.

A34 Epigenetic and transcriptional regulator gene mutations in relapsed acute myeloid leukemia. Samuli Eldfors, University of Helsinki, Helsinki, Finland.
A35  Reversible LSD1 (KDM1A) inhibition with HCl2509 is growth inhibitory in bladder cancer cell lines and causes gene expression changes that reveal rational therapeutic partners. Sumati Gupta, Huntsman Cancer Institute, Salt Lake City, Utah.

Targeting DNA Methylation and Chromatin for Cancer Therapy

March 1-4, 2018 | Atlanta, GA

Poster Session B
Saturday, March 3, 2018
12:30 p.m. – 3:00 p.m.
Grand Ballroom DEF

B02, PR13  Targeted disruption of SIN3 chromatin regulator complex function inhibits metastasis and improves survival in triple negative breast cancer. Samuel Waxman, Icahn School of Medicine at Mount Sinai, New York, NY.

B03  Thymine DNA glycosylase as a novel target for melanoma. Alfonso Bellacosa, Fox Chase Cancer Center, Philadelphia, PA.

B04  Epigenome modification of prostate adenocarcinoma by the dietary phytochemical ursolic acid in prostate specific PTEN--/-- mice. Chao Wang, Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey.

B05  Sulforaphane epigenetically demethylates the CpG sites of miR-9-3 promoter and reactivates miR-9-3 expression in human lung cancer A549 cells. David Cheng, Rutgers University, Piscataway, NJ.

B06  Aspirin treatment inhibits LINE-1 expression in human colon cancer cell line. Ekavali Ekavali, South Dakota State University, Brookings, South Dakota.

B07, PR04  DNA methylation patterns separate senescence from transformation potential and indicate cancer risk. Hariharan Easwaran, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, MD.

B08  DNA methylation changes at enhancers define master regulators in glioma progression. Houtan Noushmehr, Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, Michigan.

B09  Epigenetic mechanisms drive cellular reprogramming in pancreatic carcinogenesis. Ivonne Regel, Department of Medicine II, University Hospital, Ludwig-Maximilian University Munich, Munich, Germany.

B10  Clinically significant subgroups of Wilms tumors are defined by genome-wide DNA methylation patterns. Jack Brzezinski, Hospital for Sick Children, Toronto, Ontario, Canada.

B11  DNMT3B induction at distant site promotes breast cancer metastasis through epigenetic reprogramming. Jae Young So, NIH, Bethesda, MD.

B12  Early loss of monoubiquitylation of Histone H2B alters key immune signaling pathways promoting the progression of high-grade serous ovarian cancer. Jagmohan Hooda, University of Pennsylvania, Philadelphia, PA.

B13, PR16  The role of long noncoding RNA mediated disruption of SWI/SNF in prostate cancer. Jesse Raab, UNC Chapel Hill, Chapel Hill, NC, 27599.

B14  Epigenetic targeting of adipocytes inhibits high-grade serous ovarian cancer cell migration and invasion. Jessica Tang, Indiana University, Bloomington, IN.
The histone methyltransferase DOT1L is a potential therapeutic target in multiple myeloma. Kazuya Ishiguro, Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan.

p16 epimutation: Function in intestinal tumorigenesis and as a target for therapy. Lanlan Shen, Baylor College of Medicine, Houston, TX.

Methylation status at the SMPD3 promoter in hepatocellular carcinoma correlates with SMPD3 gene expression and liver function markers. Maarit Tiirikainen, University of Hawaii Cancer Center, Honolulu, HI.

A Trichostatin A/Sp1 mediated mechanism for the regulation of SALL2 tumor suppressor in Jurkat T leukemia cells. Matias Hepp, Universidad de Concepcion, Concepcion, BioBio, Chile.

Deregulation of DNA demethylation in inflammation and cancer. Natalia Tretyakova, University of Minnesota, Minneapolis, MN.

CRISPR screening to assess genetic vulnerabilities in mutant IDH1-dependent models of different lineages. Lindsey Rodrigues, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.

Combining enhancer DNA methylation and RNA-seq to identify gene regulatory network changes in cancer. Nicole Yeager, Cedars-Sinai Medical Center, Los Angeles, CA.

The histone methyltransferase Suv420h2 prevents the epithelial-to-mesenchymal transition (EMT) by restraining the mesenchymal program in luminal breast cancer cells. Priya Kapoor, Emory University, Atlanta, GA.

Epigenetic and genetic modification of tumor necrosis factor alpha and associated biomarkers on human prostate cancer LNCaP, PC-3 and DU145 cells induced by ursolic acid and sulforaphane. Ran Yin, Rutgers, the State University of New Jersey, Piscataway Township, NJ.

Epigenome Modification and Cancer Prevention by Curcumin in Colitis-accelerated Colon Cancer in Mice. Renyi Wu, Rutgers University, Piscataway, New Jersey.

Discovery of selective, non-covalent small molecule inhibitors of DNMT1. Melissa Pappalardi, GlaxoSmithKline, Collegeville, PA.

Potential role of the splicing factor SF3B1 in epigenetic regulation. Sandra Deliard, Temple University School of Medicine, Philadelphia, PA.

Identification of epigenetically silenced breast cancer driver genes. Shoghag Panjarian, Fels Institute, Temple University, Philadelphia, PA.

Epigenetic changes mediated by Ring1b are an important prerequisite for acinar-to-ductal metaplasia and pancreatic carcinogenesis. Simone Benitz, Department of Internal Medicine II, University Hospital, Ludwig-Maximilian University Munich, Munich, Bavaria, Germany.

Genome-wide methylation profiling of matched glioblastoma, patient-derived neurospheres, and xenograft models. Tathiane Malta, Henry Ford Hospital, Detroit, Michigan.

Aggressive glioma G-CIMP subtype is defined by loss of 5-hydroxymethylcytosine associated with genomic enhancers. Thaís Sabedot, Henry Ford Hospital, Detroit, MI.

Combination effect of sulforaphane and epigenetic alternations reagents for metastatic melanoma treatment. Tung-chin Chiang, University of Arkansas for Medical Sciences, Little Rock, AR.

Tumor-suppressive miR-145 co-repressed by TCF4-β-catennin and PRC2 complexes forms double-negative regulation loops with its negative regulators in colorectal cancer. Wei Wang, State Key Laboratory of Cancer Biology, Department of Immunology, Fourth Military Medical University, Xi’an, Shaanxi, China.
B33  MYSM1 inhibits human colorectal cancer tumorigenesis by facilitating the expression of the miR-200 family and blocking PI3K/AKT signaling. Wei Wang, State Key Laboratory of Cancer Biology, Department of Immunology, Fourth Military Medical University, Xi’an, Shaanxi, PR China.

B34  Epigenetic characteristics of ovarian cancer stem cells. Yinu Wang, Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL.

B35, PR12  Inhibition of histone methyltransferases EHMT1 and EHMT2 reduces PARP inhibitor resistance in high grade serous ovarian cancer. Zachary Watson, University of Colorado, Aurora, CO.